ESC 365 - The case for early LDL-c lowering in patients at increased CV risk: when should we start?

Open Access

The case for early LDL-c lowering in patients at increased CV risk: when should we start?

Session: Clinical choices in managing LDL-c: where do novel therapies fit in?

Topic: Pharmacology and Pharmacotherapy

Speaker: Professor P. Perrone-Filardi (Napoly, IT)

Sponsored by PACE-CME - Supported by unrestricted educational grants from Amgen and NewAmsterdam/Menarini

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Professor Pasquale Perrone-Filardi

Federico II University Hospital, Napoly (Italy)

10 presentations

3 followers

4 more presentations in this session

The remaining challenges in lowering LDL-c in patients at increased CV risk

Speaker: Professor K. Ray (London, GB)

Reaching LDL-c targets in patients at high CV risk: how well are we doing?

Speaker: Doctor J. Brandts (Aachen, DE)

Novel oral LDL-c lowering therapies on the horizon: CETP inhibition

Speaker: Professor U. Laufs (Leipzig, DE)

Discussion

Speaker: Professor K. Ray (London, GB)

Access the full session

Clinical choices in managing LDL-c: where do novel therapies fit in?

Speakers: Professor P. Perrone-Filardi, Professor K. Ray, Doctor J. Brandts, Professor U. Laufs, Professor K. Ray

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources